# APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors

> **NCT02911961** · PHASE4 · WITHDRAWN · sponsor: **Denver Health and Hospital Authority**

## Conditions studied

- Acetaminophen Exposure

## Interventions

- **DRUG:** Acetaminophen

## Key facts

- **NCT ID:** NCT02911961
- **Lead sponsor:** Denver Health and Hospital Authority
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08
- **Primary completion:** 2021-08
- **Final completion:** 2021-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to lack of enrollment and organizational desire to focus recruitment efforts on other studies.
- **Last updated:** 2021-09-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02911961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02911961, "APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02911961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*